conducted a study on the ER+/HER2-low human breast cancer mouse xenotransplantation model, and the results showed that adding ET to the combination of anti-HER3 and anti-HER2 drugs could further improve the efficacy of tumor regression (55). This evidence concerns the gene ERBB3 and breast carcinoma.